Docetaxel is under clinical development by Starpharma and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II drugs for Pancreatic Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Docetaxel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Docetaxel overview

Docetaxel (nano-formulation) is under development for the treatment of solid cancers, pancreatic cancer, gastric cancer, including non-small cell lung cancer, prostate, esophageal cancer, bile duct cancer (cholangiocarcinoma), sarcomas and melanoma of eye. It is administered through intravenous route. The drug candidate is developed based on dendrimer nanotechnology. It was also under development for the treatment of small cell lung cancer, gastro-oesophageal, breast, cervical, renal and brain cancer.

Starpharma overview

Starpharma is a biotechnology company, which researches, develops and manufactures dendrimer products for pharmaceutical, life sciences and other applications. Dendrimers are synthetic nanoscale polymers with pharmaceutical and medical uses. The company’s development programs include its DEP drug delivery, which is built around dendrimers and VivaGel portfolio. Its flagship product candidate, VivaGel, is a gel-based formulation for the treatment and prevention of bacterial vaginosis (BV) and it is also used as a vaginal microbicide to prevent the sexually transmitted infections including HIV and genital herpes. It has license arrangements with several partners including Okamoto Industries and AstraZeneca among others. The company has research facilities in Melbourne, Australia. Starpharma is headquartered in Abbotsford, Victoria, Australia

For a complete picture of Docetaxel’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 April 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.